Go Pro
→ Buy These Stocks Before August 31st (From TradeSmith) (Ad)tc pixel Free SRNE Stock Alerts

Sorrento Therapeutics (SRNE) Competitors

Sorrento Therapeutics logo
$0.0008 0.00 (0.00%)
As of 08/21/2026 03:52 PM Eastern
Compare

SRNE vs. ASLN, EVFM, NMTR, PRFX, and HEPA

Should you buy Sorrento Therapeutics stock or one of its competitors? Sorrento Therapeutics's main competitors and comparable companies include ASLAN Pharmaceuticals (ASLN), Evofem Biosciences (EVFM), 9 Meters Biopharma (NMTR), PainReform (PRFX), and Hepion Pharmaceuticals (HEPA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Sorrento Therapeutics compare to ASLAN Pharmaceuticals?

ASLAN Pharmaceuticals (NASDAQ:ASLN) and Sorrento Therapeutics (NASDAQ:SRNE) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk.

In the previous week, Sorrento Therapeutics had 1 more articles in the media than ASLAN Pharmaceuticals. MarketBeat recorded 1 mentions for Sorrento Therapeutics and 0 mentions for ASLAN Pharmaceuticals. ASLAN Pharmaceuticals' average media sentiment score of 0.00 equaled Sorrento Therapeutics'average media sentiment score.

Company Overall Sentiment
ASLAN Pharmaceuticals Neutral
Sorrento Therapeutics Neutral

Sorrento Therapeutics' return on equity of 0.00% beat ASLAN Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
ASLAN PharmaceuticalsN/A -8,454.87% -121.60%
Sorrento Therapeutics N/A N/A N/A

ASLAN Pharmaceuticals has higher earnings, but lower revenue than Sorrento Therapeutics. ASLAN Pharmaceuticals is trading at a lower price-to-earnings ratio than Sorrento Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ASLAN Pharmaceuticals$12M0.10-$44.22M-$21.92N/A
Sorrento Therapeutics$60.32M0.01-$572.84M-$0.17N/A

ASLAN Pharmaceuticals has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market. Comparatively, Sorrento Therapeutics has a beta of 0.13, meaning that its stock price is 87% less volatile than the broader market.

58.8% of ASLAN Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.0% of Sorrento Therapeutics shares are owned by institutional investors. 4.7% of ASLAN Pharmaceuticals shares are owned by insiders. Comparatively, 2.6% of Sorrento Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Sorrento Therapeutics beats ASLAN Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

How does Sorrento Therapeutics compare to Evofem Biosciences?

Evofem Biosciences (NASDAQ:EVFM) and Sorrento Therapeutics (NASDAQ:SRNE) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, risk, earnings, dividends and media sentiment.

0.2% of Evofem Biosciences shares are held by institutional investors. Comparatively, 0.0% of Sorrento Therapeutics shares are held by institutional investors. 0.0% of Evofem Biosciences shares are held by insiders. Comparatively, 2.6% of Sorrento Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Evofem Biosciences has a beta of -1.32, meaning that its stock price is 232% less volatile than the broader market. Comparatively, Sorrento Therapeutics has a beta of 0.13, meaning that its stock price is 87% less volatile than the broader market.

In the previous week, Sorrento Therapeutics had 1 more articles in the media than Evofem Biosciences. MarketBeat recorded 1 mentions for Sorrento Therapeutics and 0 mentions for Evofem Biosciences. Evofem Biosciences' average media sentiment score of 0.00 equaled Sorrento Therapeutics'average media sentiment score.

Company Overall Sentiment
Evofem Biosciences Neutral
Sorrento Therapeutics Neutral

Sorrento Therapeutics has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. Sorrento Therapeutics' return on equity of 0.00% beat Evofem Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Evofem Biosciences-46.42% -91.97% -61.93%
Sorrento Therapeutics N/A N/A N/A

Evofem Biosciences has higher earnings, but lower revenue than Sorrento Therapeutics. Evofem Biosciences is trading at a lower price-to-earnings ratio than Sorrento Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evofem Biosciences$11.39M0.09$52.98M-$0.13N/A
Sorrento Therapeutics$60.32M0.01-$572.84M-$0.17N/A

Summary

Sorrento Therapeutics beats Evofem Biosciences on 8 of the 12 factors compared between the two stocks.

How does Sorrento Therapeutics compare to 9 Meters Biopharma?

9 Meters Biopharma (NASDAQ:NMTR) and Sorrento Therapeutics (NASDAQ:SRNE) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

9 Meters Biopharma has a beta of 1.36, indicating that its share price is 36% more volatile than the broader market. Comparatively, Sorrento Therapeutics has a beta of 0.13, indicating that its share price is 87% less volatile than the broader market.

In the previous week, Sorrento Therapeutics had 1 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 1 mentions for Sorrento Therapeutics and 0 mentions for 9 Meters Biopharma. 9 Meters Biopharma's average media sentiment score of 0.00 equaled Sorrento Therapeutics'average media sentiment score.

Company Overall Sentiment
9 Meters Biopharma Neutral
Sorrento Therapeutics Neutral

9 Meters Biopharma has higher earnings, but lower revenue than Sorrento Therapeutics. Sorrento Therapeutics is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
9 Meters BiopharmaN/AN/A-$43.77M-$3.46N/A
Sorrento Therapeutics$60.32M0.01-$572.84M-$0.17N/A

22.3% of 9 Meters Biopharma shares are held by institutional investors. Comparatively, 0.0% of Sorrento Therapeutics shares are held by institutional investors. 2.4% of 9 Meters Biopharma shares are held by insiders. Comparatively, 2.6% of Sorrento Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Sorrento Therapeutics' return on equity of 0.00% beat 9 Meters Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
9 Meters BiopharmaN/A -584.97% -159.45%
Sorrento Therapeutics N/A N/A N/A

Summary

Sorrento Therapeutics beats 9 Meters Biopharma on 6 of the 10 factors compared between the two stocks.

How does Sorrento Therapeutics compare to PainReform?

Sorrento Therapeutics (NASDAQ:SRNE) and PainReform (NASDAQ:PRFX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.

Sorrento Therapeutics has a beta of 0.13, suggesting that its stock price is 87% less volatile than the broader market. Comparatively, PainReform has a beta of 1.06, suggesting that its stock price is 6% more volatile than the broader market.

0.0% of Sorrento Therapeutics shares are held by institutional investors. Comparatively, 37.3% of PainReform shares are held by institutional investors. 2.6% of Sorrento Therapeutics shares are held by company insiders. Comparatively, 34.4% of PainReform shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

PainReform has lower revenue, but higher earnings than Sorrento Therapeutics. Sorrento Therapeutics is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sorrento Therapeutics$60.32M0.01-$572.84M-$0.17N/A
PainReform$20K43.37-$5.02M-$736.66N/A

In the previous week, Sorrento Therapeutics had 1 more articles in the media than PainReform. MarketBeat recorded 1 mentions for Sorrento Therapeutics and 0 mentions for PainReform. Sorrento Therapeutics' average media sentiment score of 0.00 equaled PainReform'saverage media sentiment score.

Company Overall Sentiment
Sorrento Therapeutics Neutral
PainReform Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sorrento Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
PainReform
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Company Net Margins Return on Equity Return on Assets
Sorrento TherapeuticsN/A N/A N/A
PainReform N/A N/A N/A

Summary

PainReform beats Sorrento Therapeutics on 7 of the 10 factors compared between the two stocks.

How does Sorrento Therapeutics compare to Hepion Pharmaceuticals?

Hepion Pharmaceuticals (NASDAQ:HEPA) and Sorrento Therapeutics (NASDAQ:SRNE) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations.

In the previous week, Hepion Pharmaceuticals and Hepion Pharmaceuticals both had 1 articles in the media. Hepion Pharmaceuticals' average media sentiment score of 3.00 beat Sorrento Therapeutics' score of 0.00 indicating that Hepion Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Hepion Pharmaceuticals Very Positive
Sorrento Therapeutics Neutral

Hepion Pharmaceuticals has a beta of 1.52, meaning that its share price is 52% more volatile than the broader market. Comparatively, Sorrento Therapeutics has a beta of 0.13, meaning that its share price is 87% less volatile than the broader market.

17.2% of Hepion Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.0% of Sorrento Therapeutics shares are owned by institutional investors. 0.1% of Hepion Pharmaceuticals shares are owned by company insiders. Comparatively, 2.6% of Sorrento Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Sorrento Therapeutics' return on equity of 0.00% beat Hepion Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Hepion PharmaceuticalsN/A -812.56% -207.31%
Sorrento Therapeutics N/A N/A N/A

Hepion Pharmaceuticals has higher earnings, but lower revenue than Sorrento Therapeutics. Sorrento Therapeutics is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hepion PharmaceuticalsN/AN/A-$48.93M-$72.15N/A
Sorrento Therapeutics$60.32M0.01-$572.84M-$0.17N/A

Summary

Sorrento Therapeutics beats Hepion Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

Get Sorrento Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SRNE and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SRNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SRNE vs. The Competition

Export
MetricSorrento TherapeuticsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$441K$12.45B$7.27B$12.76B
Dividend YieldN/A2.64%2.54%11.09%
P/E Ratio0.00784.87270.6924.20
Price / Sales0.01761.74639.89109.39
Price / CashN/A92.1276.8953.23
Price / BookN/A11.8513.436.37
Net Income-$572.84M$2.80B$3.46B$347.74M
7 Day PerformanceN/A1.92%2.15%0.06%
1 Month PerformanceN/A3.70%6.18%2.86%
1 Year PerformanceN/A6.59%24.96%17.13%

Sorrento Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SRNE
Sorrento Therapeutics
N/A$0.00
flat		N/A-86.0%$441K$60.32MN/A800
ASLN
ASLAN Pharmaceuticals
N/A$0.60
flat		N/AN/A$1.23M$12MN/A30
EVFM
Evofem Biosciences
N/A$0.01
+6.7%		N/A-22.7%$1.06M$11.39MN/A120
NMTR
9 Meters Biopharma
N/AN/AN/AN/A$1.04MN/AN/A20
PRFX
PainReform
0.203 of 5 stars		$0.94
-2.9%		N/A-87.8%$890K$20KN/A4

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SRNE) was last updated on 8/22/2026 by MarketBeat.com Staff.
From Our Partners
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
Your Free Report (Inside)
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
23,281 stocks. Only ONE survived.
One American energy producer just cleared a screen of 23281 stocks for elite operating profits, double-digit r...
Monument Traders Alliance | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
The world's #2 gold miner is running on fumes [it has to buy]
Barrick, the world's second-largest gold miner, produced 7.77 million ounces in 2010. This year, output is exp...
Golden Portfolio | Sponsoredtc pixel